China Lenalidomide Markets, 2016-2020 & 2021-2025: Sales Value was CNY297.4 Million in 2020 and the CAGR of Lenalidomide from 2016 to 2020 is 98.7%
May 11, 2021 05:23 ET | Research and Markets
Dublin, May 11, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Lenalidomide Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Lenalidomide is an oral...
Outlook on the Blood Cancer Drugs Global Market to 2026 - by Product, Treatment Approach, Application and Region
January 18, 2021 05:13 ET | Research and Markets
Dublin, Jan. 18, 2021 (GLOBE NEWSWIRE) -- The "Blood Cancer Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's...
Hausfeld logo
Hausfeld Announces $55 Million Settlement in Antitrust Class Action Against Celgene
July 24, 2019 11:19 ET | Hausfeld
WASHINGTON, July 24, 2019 (GLOBE NEWSWIRE) -- Hausfeld, a global claimants’ law firm dedicated to handling complex litigation, announced today that it has reached a $55 million settlement with...
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
February 27, 2018 18:00 ET | BeiGene, LTD.
BEIJING, China, and CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
August 25, 2011 08:00 ET | BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...